ReVessel Unveils AI-Driven Digital Twin of Human Blood for Personalized Medicine
ReVessel Bridges the Gap Between Biology and Data with AI-Driven Blood Models
Summary
Health-tech company ReVessel announced the development of the world's first digital twin of human blood. This AI-powered platform simulates each individual's blood state in real time, providing advanced clinical decision support based on multi-faceted data.
Details
ReVessel has developed a 'digital twin of human blood,' which is an AI-powered model that replicates the hematologic and hemodynamic state of each individual in real time. Unlike traditional static models, this platform integrates multiple data streams—including multi-omics, pharmacokinetics (PK), and clinical indicators—to provide customized simulations tailored to a patient's unique profile. This capability allows healthcare systems to move beyond one-size-fits-all treatment decisions, enabling more nuanced, data-driven care. The digital twin engine transforms biological complexity into predictive insight, offering simulation-powered insights in under 200 milliseconds directly at the point of care, supporting faster clinical decision-making. A key feature is its design for interoperability: ReVessel supports standard clinical data formats such as EMR, FHIR, and OMOP. This allows secure integration via APIs without requiring a costly infrastructure overhaul, enabling immediate value for hospitals and health systems. The platform is currently in early-stage development and not yet commercially available. The company is actively collaborating with clinical advisors and research institutions to validate and co-develop the technology.
Original content copyright by respective publishers